JPMorgan lowered the firm’s price target on Surgery Partners (SGRY) to $28 from $38 and keeps a Neutral rating on the shares. The firm updated healthcare facilities models post the Q3 reports.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGRY:
- Surgery Partners price target lowered to $35 from $49 at RBC Capital
- Surgery Partners post-earnings selloff overdone, says Macquarie
- Surgery Partners price target lowered to $31 from $32 at Barclays
- Surgery Partners price target lowered to $34 from $35 at Macquarie
- Surgery Partners Reports Q3 Revenue Growth Amid Challenges
Questions or Comments about the article? Write to editor@tipranks.com